Text Size

A Study to Compare Tenofovir Versus Hepsera (Adefovir) for the Treatment of Hepatitis Be Antigen (HBeAg) Positive Chronic Hepatitis B

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Gilead Sciences
ClinicalTrials.gov Identifier:
NCT00116805
First received: June 30, 2005
Last updated: October 31, 2011
Last verified: October 2011
History of Changes
Results First Received: February 11, 2010  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Chronic Hepatitis B
Interventions: Drug: tenofovir disoproxil fumarate
Drug: adefovir dipivoxil

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
There were 90 enrolling sites in 15 countries. The first participant was screened on 09 June 2005, and the last participant was randomized on 15 June 2006. The last participant observation (LPO) for the primary endpoint analysis (Week 48) was 11 May 2007. The LPO for the Week 96 analysis was 27 May 2008.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Six of the 272 participants who were successfully screened and randomized discontinued prior to the first dose of study drug due to being erroneously randomized via interactive voice response system, withdrawal of consent, loss to follow-up, or failure to meet screening criteria. The screening process involved a liver biopsy.

Reporting Groups
  Description
TDF 300 mg QD Double-blind TDF 300 mg QD for 48 weeks, followed by OL TDF 300 mg for an additional 336 weeks
ADV 10 mg QD Double-blind ADV 10 mg QD for 48 weeks, then switch to OL TDF 300 mg for an additional 336 weeks

Participant Flow for 2 periods

 Period 1:   Double-blind Period Through Week 48
    TDF 300 mg QD     ADV 10 mg QD  
STARTED     176 [1]   90 [1]
COMPLETED     154 [2]   84 [2]
NOT COMPLETED     22     6  
Lost to Follow-up                 8                 2  
Protocol Violation                 1                 1  
Withdrawal by Subject                 10                 3  
Seroconversion                 2                 0  
Declined extension                 1                 0  
[1] Randomized-and-treated participants
[2] Completed through Week 48 with end-of-double-blind-treatment liver biopsy results

Period 2:   Open-Label TDF Period Through Week 96
    TDF 300 mg QD     ADV 10 mg QD  
STARTED     154 [1]   84 [1]
COMPLETED     145 [2]   83 [2]
NOT COMPLETED     9     1  
Physician Decision                 1                 0  
Lost to Follow-up                 2                 0  
Protocol Violation                 2                 0  
Safety, tolerability, or efficacy reason                 1                 0  
Seroconversion                 1                 0  
Withdrawal by Subject                 2                 1  
[1] Entered the open-label TDF period
[2] Completed through Week 96



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
TDF 300 mg QD Double-blind TDF 300 mg QD for 48 weeks, followed by OL TDF 300 mg for an additional 336 weeks
ADV 10 mg QD Double-blind ADV 10 mg QD for 48 weeks, then switch to OL TDF 300 mg for an additional 336 weeks
Total Total of all reporting groups

Baseline Measures
    TDF 300 mg QD     ADV 10 mg QD     Total  
Number of Participants  
[units: participants]
 		  176     90     266  
Age  
[units: participants]
 		     
<=18 years     3     1     4  
Between 18 and 65 years     173     89     262  
>=65 years     0     0     0  
Age  
[units: years]
Mean ± Standard Deviation 		  34  ± 11.3     34  ± 12.2     34  ± 11.6  
Gender  
[units: participants]
 		     
Female     57     26     83  
Male     119     64     183  
Region of Enrollment  
[units: participants]
 		     
United States     30     14     44  
Greece     1     2     3  
Spain     7     2     9  
Turkey     10     4     14  
Italy     0     1     1  
United Kingdom     6     1     7  
France     11     3     14  
Czech Republic     3     5     8  
Canada     17     10     27  
Poland     16     8     24  
Australia     22     6     28  
Bulgaria     17     11     28  
Germany     20     8     28  
Netherlands     6     4     10  
New Zealand     10     11     21  
Baseline Alanine Aminotransferase (ALT) above the Upper Limit of the Normal (ULN) Range [1]
[units: Participants]
 		     
Yes     169     90     259  
No     7     0     7  
Prior Lamivudine or Emtricitabine Exposure [1]
[units: Participants]
 		     
Yes     8     1     9  
No     168     89     257  
Baseline Hepatitis B Deoxyribonucleic Acid (HBV DNA) [1]
[units: Log10 copies/mL]
Mean ± Standard Deviation 		  8.64  ± 1.076     8.88  ± 0.930     8.72  ± 1.033  
Baseline Knodell Necroinflammatory Score [2]
[units: Units on a scale]
Mean ± Standard Deviation 		  8.3  ± 2.11     8.5  ± 2.07     8.4  ± 2.09  
[1] Randomized-and-treated analysis set
[2] Randomized-and-treated analysis set. Based on Knodell numerical scoring of liver biopsy specimens. This scale consists of 5 domains (Periportal with or without Bridging Necrosis [scored numerically from best to worst 0, 1, 3, 4, 5, 6, or 10]; Intralobular Degeneration and Focal Necrosis [scored best to worst 0 to 4]; Portal Inflammation [also scored best to worst 0 to 4]; and Fibrosis [also scored best to worst 0 to 4]). The necroinflammatory score is the combined score for Necrosis and Inflammation, excluding the Fibrosis score. Scores may range from 0 (best) to 14 (worst).



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) <400 Copies/mL and Histological Improvement (2-point or Higher Reduction in the Knodell Necroinflammatory Score Without Worsening in Knodell Fibrosis Score) at Week 48   [ Time Frame: Week 48 ]
  Show Outcome Measure 1

2.  Secondary:   Percentage of Participants With Histological Response at Week 48   [ Time Frame: Week 48 ]
  Show Outcome Measure 2

3.  Secondary:   Percentage of Participants With HBV DNA <400 Copies/mL at Week 48   [ Time Frame: Week 48 ]
  Show Outcome Measure 3

4.  Secondary:   Percentage of Participants With HBV DNA <400 Copies/mL at Week 96   [ Time Frame: Week 96 ]
  Show Outcome Measure 4

5.  Secondary:   Percentage of Participants With Alanine Aminotransferase (ALT) Normalization at Week 48   [ Time Frame: Week 48 ]
  Show Outcome Measure 5

6.  Secondary:   Percentage of Participants With ALT Normalization at Week 96   [ Time Frame: Week 96 ]
  Show Outcome Measure 6

7.  Secondary:   Percentage of Participants With Hepatitis B E-antigen (HBeAg) Loss/Seroconversion at Week 48   [ Time Frame: Week 48 ]
  Show Outcome Measure 7

8.  Secondary:   Percentage of Participants With HBeAg Loss or Seroconversion at Week 96   [ Time Frame: Week 96 ]
  Show Outcome Measure 8

9.  Secondary:   Percentage of Participants With Hepatitis B S-Antigen (HBsAg) Loss or Seroconversion at Week 48   [ Time Frame: Week 48 ]
  Show Outcome Measure 9

10.  Secondary:   Percentage of Participants With HBsAg Loss or Serconversion to Anti-HBs at Week 96   [ Time Frame: Week 96 ]
  Show Outcome Measure 10

11.  Secondary:   Percentage of Participants With HBV Genotypic Changes From Baseline at Week 48 (Resistance Surveillance)   [ Time Frame: Week 48 ]
  Show Outcome Measure 11

12.  Secondary:   Number of Participants With HBV Genotypic Changes From Baseline at Week 96 (Resistance Surveillance)   [ Time Frame: Week 96 ]
  Hide Outcome Measure 12

Measure Type Secondary
Measure Title Number of Participants With HBV Genotypic Changes From Baseline at Week 96 (Resistance Surveillance)
Measure Description Participants evaluated for resistance included those with HBV DNA >/= 400 copies/mL at Week 96 in TDF monotherapy, those who discontinued after Week 48 with HBV DNA >/= 400 copies/mL, and those who added emtricitabine to their open-label TDF regimen and had HBV DNA >/= 400 copies/mL at the time of the addition.
Time Frame Week 96  
Safety Issue No  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Of the participants who entered the OL TDF period, those evaluated for resistance included those with HBV DNA </= 400 copies/mL at Week 96 on TDF monotherapy, those who discontinued after Week 48 with HBV DNA >/= 400 copies/mL, and those who added emtricitabine to the OL TDF regimen and had HBV DNA >/= 400 copies/mL at the time of the addition.

Reporting Groups
  Description
TDF-TDF Double-blind TDF 300 mg QD for 48 weeks followed by open-label TDF for an additional 336 weeks.
ADV-TDF Double-blind ADV 10 mg QD for 48 weeks, then switch to open-label TDF for an additional 336 weeks.

Measured Values
    TDF-TDF     ADV-TDF  
Number of Participants Analyzed  
[units: participants]
 		  154     84  
Number of Participants With HBV Genotypic Changes From Baseline at Week 96 (Resistance Surveillance)  
[units: Participants]
 		   
Participants evaluated     18     15  
Changes at conserved sites in HBV polymerase     2     2  
Polymorphic site changes (wild-type virus)     3     1  
No genotypic changes     10     12  
Unable to be genotyped     3     1  

No statistical analysis provided for Number of Participants With HBV Genotypic Changes From Baseline at Week 96 (Resistance Surveillance)




  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Jane Anderson, Associate Director Clinical Research
Organization: Gilead Sciences
phone: 919-294-7160
e-mail: Jane.anderson@gilead.com


No publications provided by Gilead Sciences

Publications automatically indexed to this study:


Responsible Party: Gilead Sciences
ClinicalTrials.gov Identifier: NCT00116805     History of Changes
Other Study ID Numbers: GS-US-174-0103
Study First Received: June 30, 2005
Results First Received: February 11, 2010
Last Updated: October 31, 2011
Health Authority: United States: Food and Drug Administration